• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性心力衰竭患者的充血“大流行”

The Congestion "Pandemic" in Acute Heart Failure Patients.

作者信息

Mocan Daniela, Lala Radu Ioan, Puschita Maria, Pilat Luminita, Darabantiu Dan Alexandru, Pop-Moldovan Adina

机构信息

Multidisciplinary Doctoral School, Vasile Goldis Western University of Arad, 310025 Arad, Romania.

Cardiology Department, Arad County Clinical Emergency Hospital, 310037 Arad, Romania.

出版信息

Biomedicines. 2024 Apr 24;12(5):951. doi: 10.3390/biomedicines12050951.

DOI:10.3390/biomedicines12050951
PMID:38790913
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11117769/
Abstract

Congestion not only represents a cardinal sign of heart failure (HF) but is also now recognized as the primary cause of hospital admissions, rehospitalization, and mortality among patients with acute heart failure (AHF). Congestion can manifest through various HF phenotypes in acute settings: volume overload, volume redistribution, or both. Recognizing the congestion phenotype is paramount, as it implies different therapeutic strategies for decongestion. Among patients with AHF, achieving complete decongestion is challenging, as more than half still experience residual congestion at discharge. Residual congestion is one of the strongest predictors of future cardiovascular events and poor outcomes. Through this review, we try to provide a better understanding of the congestion phenomenon among patients with AHF by highlighting insights into the pathophysiological mechanisms behind congestion and new diagnostic and management tools to achieve and maintain efficient decongestion.

摘要

充血不仅是心力衰竭(HF)的主要体征,现在还被认为是急性心力衰竭(AHF)患者住院、再次住院和死亡的主要原因。在急性情况下,充血可通过各种HF表型表现出来:容量超负荷、容量重新分布或两者兼而有之。识别充血表型至关重要,因为这意味着不同的消肿治疗策略。在AHF患者中,实现完全消肿具有挑战性,因为超过一半的患者在出院时仍有残余充血。残余充血是未来心血管事件和不良结局的最强预测因素之一。通过本综述,我们试图通过强调对充血背后病理生理机制的见解以及实现和维持有效消肿的新诊断和管理工具,更好地理解AHF患者的充血现象。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06b5/11117769/fc7384b57c92/biomedicines-12-00951-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06b5/11117769/3bc482b44ab9/biomedicines-12-00951-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06b5/11117769/2bf3f8b38aa4/biomedicines-12-00951-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06b5/11117769/324ab1a40574/biomedicines-12-00951-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06b5/11117769/fc7384b57c92/biomedicines-12-00951-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06b5/11117769/3bc482b44ab9/biomedicines-12-00951-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06b5/11117769/2bf3f8b38aa4/biomedicines-12-00951-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06b5/11117769/324ab1a40574/biomedicines-12-00951-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06b5/11117769/fc7384b57c92/biomedicines-12-00951-g004.jpg

相似文献

1
The Congestion "Pandemic" in Acute Heart Failure Patients.急性心力衰竭患者的充血“大流行”
Biomedicines. 2024 Apr 24;12(5):951. doi: 10.3390/biomedicines12050951.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
A spotlight on congestion in acute heart failure: a joint session with the Romanian Society of Cardiology (part I).聚焦急性心力衰竭中的充血:与罗马尼亚心脏病学会的联合会议(第一部分)
Heart Fail Rev. 2025 Apr 29. doi: 10.1007/s10741-025-10515-0.
4
Continuous infusion versus bolus injection of loop diuretics for acute heart failure.急性心力衰竭时持续输注与大剂量注射袢利尿剂的比较。
Cochrane Database Syst Rev. 2024 May 22;5(5):CD014811. doi: 10.1002/14651858.CD014811.pub2.
5
The Effects of Burst Steroid Therapy on Short-term Decongestion in Acute Heart Failure Patients With Pro-inflammatory Activation: A Post Hoc Analysis of the CORTAHF Randomized, Open-label, Pilot Trial.冲击性类固醇疗法对伴有促炎激活的急性心力衰竭患者短期充血缓解的影响:CORTAHF随机、开放标签、试点试验的事后分析
J Card Fail. 2025 Feb;31(2):354-366. doi: 10.1016/j.cardfail.2024.09.002. Epub 2024 Sep 29.
6
Systemic Inflammatory Response Syndrome全身炎症反应综合征
7
Ultrafiltration for acute heart failure.超滤治疗急性心力衰竭。
Cochrane Database Syst Rev. 2022 Jan 21;1(1):CD013593. doi: 10.1002/14651858.CD013593.pub2.
8
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
9
Ventilator Management呼吸机管理
10
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.

引用本文的文献

1
Impact of optimal medical therapy in heart failure certification for hospitalists on guideline-directed medical therapy utilization.针对住院医师的心力衰竭认证中的优化药物治疗对指南指导药物治疗利用情况的影响。
World J Cardiol. 2025 Jun 26;17(6):107102. doi: 10.4330/wjc.v17.i6.107102.
2
Soluble CD146 in Heart Failure: Pathophysiological Role and Diagnostic Potential.心力衰竭中的可溶性CD146:病理生理作用及诊断潜力
Biomedicines. 2025 Jun 3;13(6):1370. doi: 10.3390/biomedicines13061370.
3
Assessment of Decongestion Status Before Discharge in Acute Decompensated Heart Failure: A Review of Clinical, Biochemical, and Imaging Tools and Their Impact on Management Decisions.

本文引用的文献

1
Acetazolamide for acute heart failure: is ADVOR a riddle wrapped in a mystery inside an enigma?乙酰唑胺用于治疗急性心力衰竭:ADVOR研究是一个谜团包裹在一个谜之中再置于一个不可解的事物里吗?
Eur Heart J. 2023 Oct 1;44(37):3683-3685. doi: 10.1093/eurheartj/ehad560.
2
Global Public Health Burden of Heart Failure: An Updated Review.心力衰竭的全球公共卫生负担:最新综述
Card Fail Rev. 2023 Jul 27;9:e11. doi: 10.15420/cfr.2023.05. eCollection 2023.
3
sST2 and Heart Failure-Clinical Utility and Prognosis.可溶性ST2与心力衰竭——临床应用及预后
急性失代偿性心力衰竭患者出院前充血状态评估:临床、生化及影像学工具综述及其对管理决策的影响
Medicina (Kaunas). 2025 Apr 28;61(5):816. doi: 10.3390/medicina61050816.
4
Carbohydrate antigen 125 determined on arrival at the emergency department correlates with severity of decompensation and adverse outcomes in patients with acute heart failure.急诊科就诊时测定的糖类抗原125与急性心力衰竭患者失代偿的严重程度及不良预后相关。
Intern Emerg Med. 2025 May 5. doi: 10.1007/s11739-025-03932-4.
5
Unveiling the Systemic Impact of Congestion in Heart Failure: A Narrative Review of Multisystem Pathophysiology and Clinical Implications.揭示心力衰竭中充血的全身影响:多系统病理生理学及临床意义的叙述性综述
J Cardiovasc Dev Dis. 2025 Mar 31;12(4):124. doi: 10.3390/jcdd12040124.
6
Addressing 'Residual Congestion' to Improve Prognosis After Acute Heart Failure Decompensation.解决“残余充血”问题以改善急性心力衰竭失代偿后的预后。
Card Fail Rev. 2025 Mar 24;11:e06. doi: 10.15420/cfr.2024.24. eCollection 2025.
J Clin Med. 2023 Apr 26;12(9):3136. doi: 10.3390/jcm12093136.
4
A Suggested Model for the Vulnerable Phase of Heart Failure: Assessment of Risk Factors, Multidisciplinary Monitoring, Cardiac Rehabilitation, and Addressing the Social Determinants of Health.心力衰竭脆弱期的建议模型:风险因素评估、多学科监测、心脏康复及解决健康的社会决定因素
Cureus. 2023 Feb 28;15(2):e35602. doi: 10.7759/cureus.35602. eCollection 2023 Feb.
5
Soluble CD146 in the detection and grading of intravascular and tissue congestion in patients with acute dyspnoea: analysis of the prospective observational Lithuanian Echocardiography Study of Dyspnoea in Acute Settings (LEDA) cohort.可溶性 CD146 在急性呼吸困难患者血管内和组织充血检测和分级中的作用:前瞻性观察性立陶宛急性呼吸困难心脏超声研究(LEDA)队列分析。
BMJ Open. 2022 Sep 1;12(9):e061611. doi: 10.1136/bmjopen-2022-061611.
6
SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials.SGLT2抑制剂在急性心力衰竭中的应用:一项随机对照试验的荟萃分析
Healthcare (Basel). 2022 Nov 23;10(12):2356. doi: 10.3390/healthcare10122356.
7
Getting ahead of the game: in-hospital initiation of HFrEF therapies.抢占先机:院内启动射血分数降低的心力衰竭(HFrEF)治疗
Eur Heart J Suppl. 2022 Dec 19;24(Suppl L):L38-L44. doi: 10.1093/eurheartjsupp/suac120. eCollection 2022 Dec.
8
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.升阶梯治疗急性心力衰竭指南导向的药物治疗的安全性、耐受性和疗效(STRONG-HF):一项多中心、开放标签、随机试验。
Lancet. 2022 Dec 3;400(10367):1938-1952. doi: 10.1016/S0140-6736(22)02076-1. Epub 2022 Nov 7.
9
Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology.心力衰竭中的充血:基于循环生物标志物的观点。来自心力衰竭协会、欧洲心脏病学会的生物标志物工作组的综述。
Eur J Heart Fail. 2022 Oct;24(10):1751-1766. doi: 10.1002/ejhf.2664. Epub 2022 Sep 7.
10
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.乙酰唑胺治疗急性失代偿性心力衰竭伴容量超负荷
N Engl J Med. 2022 Sep 29;387(13):1185-1195. doi: 10.1056/NEJMoa2203094. Epub 2022 Aug 27.